News

Episode 4 of the AUPN Leadership Minute features Clifton L. Gooch, MD, of the University of South Florida; and Robin Brey, MD, of the University of Texas Health Science Center at San Antonio. [WATCH TIME: 3 minutes]

Data from this post-hoc analysis show slight differences between repeated administration of 1 and 2 doses of midazolam.

No patient with CDKL5 Deficiency Disorder developed valvular heart disease or pulmonary arterial hypertension while being treated with fenfluramine.

Interim data from a real-world study suggest that adjunctive treatment with brivaracetam is well-tolerated and may improve quality of life over 12 months for those with focal seizures.

The data suggest that some patients with partial-onset seizures may benefit from lower doses to mitigate treatment emergent adverse events, but these must be tailored to each patient.

The pediatric neurologist and epilepsy specialist at Children’s Hospital Colorado detailed the results of study of fenfluramine in patients with Lennox-Gastaut syndrome.

The safety profile of diazepam remained similar to what was previously observed, but generally, more patients in the concomitant benzodiazepine subgroup experienced more TEAEs.

Here's what is coming soon to NeurologyLive.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how high rates of seizure reduction were seen in treating drug resistant epilepsy.

Top line results from the retrospective EXPERIENCE study of brivaracetam are expected to read out in early 2021.

The GW Pharmaceuticals product has shown confirmed efficacy in LGS, though the study failed to produce a firm conclusion regarding its efficacy in other drug-resistant epilepsies.

The director of pediatric epilepsy at the Northeast Regional Epilepsy Group discussed his study presented at AES 2020 which involved the effectiveness of diazepam nasal spray regardless of treatment regimen.

Zogenix’s fenfluramine (Fintepla) appears to provide durable and profound reductions in monthly convulsive seizure frequency for those with Dravet syndrome out to 3 years.

The initial study results may provide the basis for future evaluation as a step towards patient empowerment and objective epilepsy diagnostics for broad application.

Neurology News Network for the week ending December 5, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 4, 2020.

The neurologist from Universitätsmedizin Berlin and Berlin Institute of Health detailed his study from AES 2020 on using wristband sensor data to forecast seizures.

High retention rates and number of patients remaining seizure-free for prolonged periods indicated the efficacy of cenobamate in treating focal seizures.

Fenfluramine was particularly effective in reducing generalized tonic-clonic seizure frequency in patients with Lennox-Gastaut syndrome, with a push for regulatory submission in the future.

High compliance rates and well-tolerance of perampanel indicate its efficacy as a treatment for partial onset seizures.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Merle Diamond, MD.

Study author Luc Evers and coauthor Bastiaan R. Bloem, MD, PhD, FRCPE, offer insight into the findings of a recent study assessing early treatment in PD.

The managing director of the Interdisciplinary Brain Center at Massachusetts General Hospital discussed the process of determining the best situations for use of AMX0035.

Stephen Cunnane, PhD, Research Center on Aging, Universite de Sherbrooke, discussed the ketogenic drink used in his recent study and the action of ketogenic diets.

The pediatric neurologist at Montefiore Health System provided her thoughts on the importance of Infantile Spasms Awareness Week.

In non-demented patients with Parkinson disease, hippocampal subfields showed associations with memory, spatial working memory, language and executive functions, and CSF tau levels.

The chief medical advisor for the Muscular Dystrophy Association discussed the organization’s recent annual telethon and the efforts to inform the public about these diseases.

Researchers from USC propose a direct neurotoxic effect of particulate matter smaller than 2.5 μm.

The executive director of the Norman Fixel Institute for Neurological Diseases discussed the role insurance companies play within the system for approving neurological devices for rare diseases.

Data from more than 37k patients in the UK Biobank study suggests hypertension in midlife was linked to an increased risk of white matter hyperintensities later in life.